AIMS: To determine the bioavailability of gentamicin to the lung following inhalation from two jet nebulizers. METHODS: Serial urine samples were obtained from 10 volunteers after a 80 mg dose given orally, nebulized from a Pari LC + (PARI) and MicroNeb III (MN) devices, or after a 40 mg intravenous dose. In vitro aerodynamic characteristics of the nebulized doses were also determined. RESULTS: The mean (SD) absolute gentamicin lung bioavailalibility following delivery by PARI and MN devices was 1.4 (0.4) and 1.7 (0.5) %. The mass median aerodynamic diameter (MMAD) of the drug particles from the PARI and MN systems was 8.6 (0.6) and 6.7 (0.5) microm and the corresponding fine particle doses (FPD) were 10.2 (2.8) and 11.7 (1.5) mg. CONCLUSIONS: The MMAD and FPD data reflect the poor lung deposition of gentamicin identified by urinary excretion.
RCT Entities:
AIMS: To determine the bioavailability of gentamicin to the lung following inhalation from two jet nebulizers. METHODS: Serial urine samples were obtained from 10 volunteers after a 80 mg dose given orally, nebulized from a Pari LC + (PARI) and MicroNeb III (MN) devices, or after a 40 mg intravenous dose. In vitro aerodynamic characteristics of the nebulized doses were also determined. RESULTS: The mean (SD) absolute gentamicin lung bioavailalibility following delivery by PARI and MN devices was 1.4 (0.4) and 1.7 (0.5) %. The mass median aerodynamic diameter (MMAD) of the drug particles from the PARI and MN systems was 8.6 (0.6) and 6.7 (0.5) microm and the corresponding fine particle doses (FPD) were 10.2 (2.8) and 11.7 (1.5) mg. CONCLUSIONS: The MMAD and FPD data reflect the poor lung deposition of gentamicin identified by urinary excretion.
Authors: J Boe; J H Dennis; B R O'Driscoll; T T Bauer; M Carone; B Dautzenberg; P Diot; K Heslop; L Lannefors Journal: Eur Respir J Date: 2001-07 Impact factor: 16.671
Authors: P F Dequin; F Faurisson; E Lemarié; F Delatour; S Marchand; C Valat; E Boissinot; C de Gialluly; P Diot Journal: Eur Respir J Date: 2001-08 Impact factor: 16.671
Authors: Michael J Asmus; Barbara A Stewart; Gary Milavetz; Mary E Teresi; Seung-Ho Han; Deli Wang; Richard C Ahrens Journal: Pharmacotherapy Date: 2002-05 Impact factor: 4.705
Authors: Abdulsalam I Al-Amoud; Brian J Clark; Henry Chrystyn Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2002-03-25 Impact factor: 3.205
Authors: Michael T Newhouse; Peter H Hirst; Sarma P Duddu; Yulia H Walter; Thomas E Tarara; Andrew R Clark; Jeffry G Weers Journal: Chest Date: 2003-07 Impact factor: 9.410
Authors: Elizabeth A Clemmons; Deborah Chavez; Laura Condel; John W Dutton; Sharon Price; Robert Lanford Journal: J Vet Pharmacol Ther Date: 2021-05-08 Impact factor: 1.567